For higher SMI, this included decreased cardiac dysrhythmias (OR, 0.59 [0.55–0.64]; P < 0.0001 [PheWAS]), decreased hypopotassaemia (hypokalaemia) (OR, 0.59 [0.54–0.64]; P < 0.0001 [PheWAS]), decreased epilepsy (OR, 0.59 [0.50–0.70]; P < 0.0001 [PheWAS]), and increased elevated prostate-specific antigen (OR, 1.84 [1.47–2.31]; P < 0.0001 [PheWAS]). The gene discussed is KLK3; the disease is epilepsy.